Trends in neoadjuvant chemotherapy use and oncological outcomes for muscle-invasive bladder cancer in Japan: a multicenter study

Anan, Go; Hatakeyama, Shingo; Fujita, Naoki; Iwamura, Hiromichi; Tanaka, Toshikazu; Yamamoto, Hayato; Tobisawa, Yuki; Yoneyama, T.; Yoneyama, Takahiro; Hashimoto, Yasuhiro; Koie, Takuya; Ito, Hiroyuki; Yoshikawa, Kunio; Kawaguchi, Toshiaki; Sato, Makoto; Οhyama, Chikara

doi:10.18632/oncotarget.20991

Cited by 30 publications

(30 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This could be a result of small percentage of Asians in this cohort. In fact, a large study from Japan showed similar stage distribution to Caucasians in TCGA cohort and similar mean age at diagnosis to Caucasians in our study [23].…”

Section: Discussionsupporting

confidence: 86%

Detailed clinical data of The Cancer Genome Atlas muscle-invasive bladder cancer database with focus on gender and ethnic stratification

Nativ¹,

Halachmi²,

Ghantous³

et al. 2018

A Rare Benign Lesion in the Lung: Clear Cell “Sugar” Tumor (CCST)

View full text Add to dashboard Cite

Introduction: Bladder cancer is one of the most common neoplasms, especially in men. About 25% of the patients present with the more aggressive type of bladder cancer, the muscle-invasive type, which carries a significant risk of death. The Cancer Genome Atlas (TCGA) had recently published extensive genomic data of 412 muscle-invasive bladder cancer (MIBC) patients, with modest clinical information. The aim of the current study was to analyze several aspects of the clinical data of TCGA bladder cancer database. Methods: Using NCI Genomic Data Commons portal and cBioPortal, we extracted data on 412 patients with MIBC from the TCGA database. We then analyzed and statistically compared these data using different statistical methods. Aside from clinical data, we also extracted data on disease-free and overall survival. Results: The database included 104 female patients and 297 male patients. The vast majority were Caucasians (79.0%), followed by Asians (11%) and African-Americans (5.5%). The female group was older than the male group (70.0 vs 67.3 years, P=0.02). Incidental prostate cancer was seen in 82 male patients (27.6%). Kaplan-Meier curves for disease-free survival and overall survival showed no difference between male and female patients, and no difference between the three ethnics groups. Conclusions: TCGA provides an invaluable source for genomic alterations of MIBC. In this study, we have shown that it also provides adequate clinical information that can be compared with genomic data and future studies. No statistically significant differences were shown in disease-free and overall survival between male and female patients in the TCGA MIBC database.

show abstract

Section: Discussionsupporting

confidence: 86%

Detailed clinical data of The Cancer Genome Atlas muscle-invasive bladder cancer database with focus on gender and ethnic stratification

Nativ¹,

Halachmi²,

Ghantous³

et al. 2018

A Rare Benign Lesion in the Lung: Clear Cell “Sugar” Tumor (CCST)

View full text Add to dashboard Cite

show abstract

“…Contrary to our data and that of the Koreans is the NAC utilization rate in Japan. A recent publication from Anan et al found 83% utilization rate over the past decade 17 . It should be noted however that 83% of their patient's cohort received carboplatin based NAC, a regimen not recommended in the United States 7 .…”

Section: Cuaj -Original Researchmentioning

confidence: 99%

Trends and disparities in the use of neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma

Duplisea

Mason

Reichard

et al. 2018

CUAJ

View full text Add to dashboard Cite

Introduction: Neoadjuvant chemotherapy (NAC) prior to radical or partial cystectomy is considered the standard of care for eligible patients with muscle-invasive urothelial carcinoma. Despite guideline recommendations, adoption of NAC has historically been low, although prior studies have suggested that use is increasing. In this contemporary study, we examine trends in the use of NAC and explore factors associated with its receipt. Methods: We identified patients in the National Cancer Database who underwent radical or partial cystectomy for cT2-cT4N0M0 urothelial carcinoma from 2006-2014. The proportion of patients receiving NAC during each year was examined. Logistic regression models were used to evaluate clinical and socioeconomic factors associated with the receipt of NAC. Results: A total of 18 188 patients were identified who underwent radical or partial cystectomy for muscle-invasive bladder cancer. Overall, 3940 (21.7%) received NAC. We noted a significant increase in the use of NAC over time, from 9.7% in 2006 to 32.2% in 2014. Factors associated with lower use of NAC include older age, higher comorbidity score, lower cT stage, lower hospital radical cystectomy volume, treatment at a non-academic facility, lower patient income, and receipt of partial cystectomy (all p<0.001). Interestingly, neither sex nor race were associated with receipt of NAC. Conclusions: Use of NAC has increased significantly over time to a modest rate of 32%. However, disparities still exist in the receipt of NAC and future efforts aimed at mitigating these disparities are warranted.

show abstract

“…We selected three courses of neoadjuvant GCb and this patient obtained the pathological complete response. Although inferior efficacy of a carboplatin‐based regimen has been suggested, our previous study showed a low toxicity GCb regimen facilitated in completion of NAC, prevention of the delay in RC, and resulted in a favorable oncological and QOL outcome . Therefore, neoadjuvant GCb might be an alternative option for MIBC patients with renal implement.…”

Section: Discussionmentioning

confidence: 94%

“…MIBC patients with a history of pelvic irradiation have been reported with more advanced disease than de novo MIBC . Cisplatin‐based NAC improves survival outcomes in patients with MIBC . However, the efficacy of NAC for irradiation‐related MIBC remains unclear.…”

Section: Discussionmentioning

confidence: 99%

Robot‐assisted radical cystectomy in a patient with muscle‐invasive bladder cancer following radiotherapy for prostate cancer

et al. 2019

Self Cite

View full text Add to dashboard Cite

Abbreviations & Acronyms GCb = gemcitabine plus carboplatin IMRT = intensity-modulated radiation therapy MIBC = muscle-invasive bladder cancer NAC = neoadjuvant chemotherapy PC = prostate cancer POD = postoperative day QOL = quality of life RARC = robot-assisted radical cystectomy RARP = robotic-assisted radical prostatectomy RC = radical cystectomy RT = radiotherapy Correspondence: ShingoIntroduction: Muscle-invasive bladder cancer following radiotherapy for prostate cancer is rare. We reported a case of muscle-invasive bladder cancer who underwent robot-assisted radical cystectomy following radiotherapy for prostate cancer. Case presentation: A 72-year-old man was referred to our division with a muscleinvasive bladder cancer. He had a history of intensity-modulated radiation therapy for localized prostate cancer. After three courses of platinum-based neoadjuvant chemotherapy, he obtained a radiologic complete response. He elected for robotassisted radical cystectomy, standard lymph node dissection, and intracorporeal ileal conduit urinary diversion. Pathological findings revealed no residual tumor within the bladder and residual tumor in the prostate. He had discharged without any complications; and quality of life had improved. Conclusion: A robot-assisted approach might be a potential option for well-selected patients with muscle-invasive bladder cancer who have previously received radiotherapy for localized prostate cancer.Although surgical treatment for patients with MIBC who have previously received RT for PC is challenging, this report indicates a robot-assisted approach might be a potential option for well-selected patients with MIBC who have previously received RT for localized PC.

show abstract

Trends in neoadjuvant chemotherapy use and oncological outcomes for muscle-invasive bladder cancer in Japan: a multicenter study

Cited by 30 publications

References 41 publications

Detailed clinical data of The Cancer Genome Atlas muscle-invasive bladder cancer database with focus on gender and ethnic stratification

Detailed clinical data of The Cancer Genome Atlas muscle-invasive bladder cancer database with focus on gender and ethnic stratification

Trends and disparities in the use of neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma

Robot‐assisted radical cystectomy in a patient with muscle‐invasive bladder cancer following radiotherapy for prostate cancer

Contact Info

Product

Resources

About